S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a potent, selective and competitive antagonist at dopamine D4 receptors: An in vitro and in vivo comparison with L 745,870 (3- (4-[4-chlorophenyl]piperazin-1yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 1, 1998, Pages 167-186

  Millan, Mark J ^a,c   Newman Tancredi, Adrian ^a   Brocco, Mauricette ^a   Gobert, Alain ^a   Lejeune, Françoise ^a   Audinot, Valérie ^a   Rivet, Jean Michel ^a   Schreiber, Rudy ^a   Dekeyne, Anne ^a   Spedding, Michael ^a   Nicolas, Jean Paul ^b   Peglion, Jean Louis ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b Molec and Cellualr Pharmacol Dept   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2,3 DIHYDROBENZO[1,4]DIOXIN 6 YL)PIPERAZIN 1 YLMETHYL]INDAN 2 YL; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE; APOMORPHINE; COCAINE; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR BLOCKING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METHYLPHENIDATE; NORADRENALIN; OXIDOPAMINE; PHENCYCLIDINE; QUINPIROLE; RACLOPRIDE; SEROTONIN; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DRUG POTENCY; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYNDROME; FRONTAL CORTEX; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMBIC CORTEX; LOCOMOTION; MALE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; ROTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BASAL GANGLIA DISEASES; BODY TEMPERATURE; BRAIN; DIOXINS; DOPAMINE; DOPAMINE ANTAGONISTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; MICE; PIPERAZINES; PYRIDINES; PYRROLES; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECEPTORS, SIGMA; SALICYLAMIDES; SEROTONIN;

EID: 0032468255     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (125)

1. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949.
2. Akunne HC, Whetzel SZ, Wiley JN, Corbin AE, Ninteman FW, Tecle H, Pei Y, Pugsley TA and Heffner TG (1997) The pharmacology of the novel and selective sigma ligand, PD 144,418. Neuropharmacology 36:51-62.
3. Andreasen NC (1996) Pieces of the schizophrenia puzzle fall into place. Neuron 16:697-700.
4. 4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res 752:26-34.
5. 4 receptor variants. J Neurochem 65:1157-1165.
6. 2 receptors. Lett Nature (Lond) 377:424-428.
7. 4 dopamine receptors. Am Soc Neurosci 22:185.15.
8. Ben-Jonathan N, Arbogast LA, Hyde JF (1989) Neuroendocrine regulation of prolactin release. Prog Neurobiol 33:399-447.
9. 2 receptor mRNA. Brain Res 564:203-219.
10. 2 receptor antagonist L-741,626. Br J Pharmacol 119:1491-1497.
11. 4 antagonists. J Med Chem 39:1946-1948.
12. 4 receptor antagonist. Trends Pharmacol Sci 18:186-188.
13. British Isles Raclopride Study Group (1992) A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. Acta Psychiatr Scand 86:391-398.
14. Cenci MA, Kalén P, Mandel RJ and Björklund A (1992) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: A microdialysis study in the rat. Brain Res 581:217-228.
15. 4 receptors. J Neurochem 63:62-65.
16. Chua SE, Wright IC, Poline J-B, Liddle PF, Murray RM, Frackoniak RSJ, Friston KJ and McGuire PK (1997) Grey matter correlates of syndromes in schizophrenia. Br J Psychiatry 170:406-410.
17. 3R receptor knockout mice. Am Soc Neurosci 22:523.9.
18. Creese I and Fraser CM (1987) Receptor Biochemistry and Methodology, vol. 8: Dopamine Receptors. p. 261, Alan R. Liss Inc., New York.
19. Cunningham-Owens DC (1996) Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 51:895-930.
20. 4 dopamine receptor in brain with sequence-specific antibodies. Mol Brain Res 45:1-12.
21. 3 receptor in the rat brain. Neuroscience 65:731-745.
22. El Mestikawy S, Glowinski J and Hamon M (1986) Presynaptic dopamine autoreceptors control tyrosine hydroxylase activation in depolarized striatal dopammergic terminals. J Neurochem 46:12-22.
23. 4 selective antagonist, U-101387G, blocks amphetamine sensitization in rats: Behavioural and biochemical changes. Am Soc Neurosci 22:1773.
24. 3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261-269.
25. Gerlach J (1991) New antipsychotics: Classification, efficacy and adverse effects. Schizophr Bull 17:289-309.
26. Giuliani D and Ferrari F (1997) Involvement of dopamine receptors in the antipsychotic profile of (-)eticlopride. Physiol Behav 61:563-567.
27. 3 (auto) receptor inhibits dopamine release in the frontal cortex of freely moving rats in vivo. J Neurochem 66:2209-2212.
28. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899-913.
29. Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L and Julian MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84:413-429.
30. Gobert A, Rivet J-M, Cistarelli L and Millan MJ (1997) Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem 68:1326-1329.
31. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC and Weinberger DR (1993) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48.
32. 4 receptors and their antagonists. Med Res Rev 16:507-526.
33. 2 dopamine receptors. Br J Pharmacol 121:731-736.
34. 1-binding site. Proc Natl Acad Sci USA 93:8072-8077.
35. 4 receptors in rat brain. Am Soc Neurosci 22:329.3.
36. 4 receptor antagonist induces c-fos expression in mouse cortex. Am Soc Neurosci 22:202.1.
37. Haycock JW and Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple site phosphorylation in vivo and in synaptosomes. J Biol Chem 266:5650-5657.
38. Heiman-Patterson TD (1993) Neuroleptic malignant syndrome and malignant hyperthermia. Med Clin North Am 77:477-492.
39. 4 receptor antagonist. NeuroReport 7:2543-2546.
40. 4 selective dopamine antagonist produces clozapine-like effects on c-fos mRNA and dopamine levels in rat brain. Am Soc Neurosci 22:1771.
41. 2 receptors to neuronal circuits in human brain: Insights into schizophrenia. Neuropsychopharmacol 16:375-384.
42. Kahn RS and Davis KL (1995) New developments in dopamine and schizophrenia, in The Fourth Generation of Progress, (Bloom FE and Kupfer DJ eds) pp 1215-1228, Raven Press, Ltd, New York.
43. Kekuda R, Prasad PD, Fei Y-J, Leibach FH and Ganapathy V (1996) Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Comm 229:553-558.
44. 4 antagonist (L 745,870) in acutely psychotic schizophrenic patients. New Clinical Drug Evaluation Unit, 36th Annual Meeting, Boca Raton, FL.
45. 4 receptor. J Med Chem 39:1941-1942.
46. 3H]-NGD-94-1. Am Soc Neurosci 22: 621.14.
47. 2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. NeuroReport 7:1945-1948.
48. 4 receptor. J Neurochem 68:804-812.
49. 3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol 275:R7-R9.
50. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurons in the rat. J Pharmacol Exp Ther 280:1241-1249.
51. 4 receptor repeats. Nature (Lond) 360:424.
52. 3 receptors. Mol Pharmacol 43:749-754.
53. 4 receptor. Mol Brain Res 29:157-167.
54. 4 receptor in human cerebral cortex and striatum. J Neurochem 66:915-919.
55. 1 sites. Eur J Pharmacol 301:31-40.
56. 4 receptor in the mouse brain. Am Soc Neurosci 22:621.11.
57. 2A receptors. Eur J Pharmacol 280:R9-R11.
58. 2 dopamine receptor. Mol Cell Endocrinol 36:201-209.
59. Meador-Woodruff JH, Damask BS, Wang J, Haroutunian V, Davis KL and Watson SJ (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15:17-29.
60. Meltzer LT, Christoffersen CL, Serpa TA, Razmpour A and Heffner TG (1992) Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs. Neuropharmacology 31:961-967.
61. 4-selective antagonist, U-101387G. Am Soc Neurosci 22:697.16.
62. 4 receptor-selective antagonist. J Pharmacol Exp Ther 279:1392-1403.
63. 2 receptor-deficient mice. Neuroscience 79:323-327.
64. 3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321:R7-R9.
65. Millan MJ, Monneyron S, Schreiber R and Dekeyne A (1997b) A drug discrimination comparison of the novel antipsychotic, S 16924, to clozapine, in rats. J Psychopharmacol 11:A.76.
66. Millan MJ, Newman-Tancredi A, Audinot V, Brocco M, Gobert A, Rivet J-M and Peglion J-L (1996) S 18126, a novel, potent and selective antagonist at human (h) recombinant dopamine (DA) hD4 receptors. Am Soc Neurosci 22:697.3.
67. 2A-adrenergic receptors in relation to modulation of cortical monoamine release and potential antidepressant properties. J Pharmacol Exp Ther 282:132-147.
68. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
69. 1A receptors in vivo. J Pharmacol Exp Ther 273:1418-1427.
70. 7 isomerase. Br J Pharmacol 121:1-6.
71. Moghaddam B and Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: An in vivo microdialysis study. J Neurochem 54:1755-1760.
72. 4 receptors in GABAergic neurons of the primate brain. Nature (Lond) 381:245-248.
73. 4 gene in post-mortem frontal cortex from control and schizophrenics. Neurosci Lett 219: 163-166.
74. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 15:2186-2191.
75. Nasello AG, Vanzeler ML and Felicio LF (1991) A comparison of bromopride and domperidone effects on rat conditioned avoidance and motor activity. Pharmacol Toxicol 68:46-50.
76. 4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282:181-191.
77. 4 receptors. Eur J Pharmacol 319:379-383.
78. 2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride and phenoxybenzamine. Neuropsychopharmacology 15:54-61.
79. Nomikos GG, Iurlo M, Andersson JL, Kimura K and Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147-156.
80. 4 receptors. J Pharmacol Exp Ther 277:186-192.
81. 4 receptor: Sequence, gene structure, and demonstration of expression in the cardiovascular system. The New Biol 4:137-146.
82. 4 receptor antagonists, schizophrenia and beyond? Eur Neuropsychopharmacol 7:S120-S121.
83. 4 receptor. Mol Pharmacol 50:1658-1664.
84. 4 receptor antagonist. Br J Pharmacol, 119:30P.
85. Paul S and Purdy RH (1992) Neuroactive steroids. FASEB J 6:2311-2322.
86. 4 knockout mice. Am Soc Neurosci 22:68.10.
87. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney, Australia.
88. 4 receptors, alters mesocorticolimbic dopamine release without altering nerve impulse rate. Am Soc Neurosci 22:1772.
89. Poncelet M, Santucci V, Paul R, Gueudet C, Lavastre S, Guitard J, Steinberg R, Terranova JP, Brelière JC, Soubrié P and Le Fur G (1993) Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A. Neuropharmacology 32:600-615.
90. 3H]NGD 94-1. J Pharmacol Exp Ther 282:1020-1027.
91. 4 receptors. Am Soc Neurosci 22:523.10.
92. 4 receptors in drug-treated schizophrenia. Eur J Pharmacol 281:R5-R6.
93. Rivet J-M, Gobert A, Cistarelli L, Girardon S, Muller O, Lavielle G and Millan MJ (1996) The novel, atypical antipsychotic, S 16924, enhances dopamine (DA) and noradrenaline (NAD) release, and decreases serotonin (5-HT) release, in frontal cortex of freely-moving rats. Am Soc Neurosci 22:467.1.
94. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368.
95. 4 receptors. J Med Chem 39:1943-1945.
96. 4 receptors are supersensitive to ethanol, cocaine and methamphetamine. Cell 90:991-1001.
97. 2) using the antagonistic properties of new benzamides. J Pharmacol Exp Ther 36:373-377.
98. 3 receptors in the effects of dopamine agonists on operant behaviour in rats. Behav Pharmacol 7:477-482.
99. 3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275:1239-1246.
100. 4 receptors by 2-fold in rats. Eur J Pharmacol 289:67-72.
101. 1A agonists. J Pharmacol Exp Ther 273:101-112.
102. 3H]nemonapride. J Neurochem 64:1413-1415.
103. 4 receptors. Neuropsychopharmacology 16:93-135.
104. 4 receptors elevated in schizophrenia. Nature (Lond) 365:441-445.
105. 125I]epidepride. Eur J Pharmacol 286:R3-R5.
106. 4. Neuropsychopharmacology 7:261-284.
107. Sokoloff P and Schwartz J-C (1995) Novel dopamine receptors half a decade later. Trends Pharmacol Sci 16:270-275.
108. 2 receptor. Eur J Pharmacol 225:331-337.
109. Steele JW, Faulds D and Sorkin EM (1993) Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. Drug and Aging 3:460-478.
110. 4 antagonist, U-101387G, on locomotor activity and brain monoamine neurochemistry in the rat. Am Soc Neurosci 22: 697.17.
111. Tallman JF (1997) NGD 94-1: A specific dopamine-4-receptor antagonist. Adv Pharmacol 42:490-492.
112. 4 receptor. J Pharmacol Exp Ther 282:1011-1019.
113. 4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 268:495-502.
114. 4 receptors in rat forebrain. NeuroReport 8:3423-3426.
115. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci 17:2519-2530.
116. 4 receptors. J Med Chem 40:13.
117. Van Kammen D, Peters J, Yao J, Van Kammen WB, Neylan T, Shaw D and Linnoila M (1990) Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry 47:161-168.
118. 4 receptor with high affinity for the antipsychotic clozapine. Nature (Lond) 350:610-614.
119. 2 receptors in motor function. Eur J Pharmacol 231:61-68.
120. 5 dopamine receptor have similar laminar distributions in the primate prefrontal cortex. Am Soc Neurosci 22:621.12.
121. Wang RY (1981) Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res Rev 3:123-140.
122. 3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm 94:11-19.
123. Wyrick SD and Booth RG (1995) Progress in sigma receptor research. Drugs Future 20:1033-1044.
124. 1 sites. J Neurosci 15:731-736.
125. 4 selective dopamine antagonist with in vitro and in vivo profile suggestive of an atypical antipsychotic. Am Soc Neurosci 22:697.1.